Perioperative Combination Chemotherapy Versus Chemoradiation for Locally Advanced EGJ Adenocarcinoma

Sun Yat-sen University logo

Sun Yat-sen University

Status and phase

Not yet enrolling
Phase 3

Conditions

Neoplasms
Esophagogastric Junction Disorder

Treatments

Drug: Perioperative FOLFOX
Radiation: chemoradiation with weekly 5Fu and oxaliplatin
Drug: Perioperative mFLOT

Study type

Interventional

Funder types

Other

Identifiers

NCT03961841
SAHMO202

Details and patient eligibility

About

Patients with histologically confirmed esophagogastric junction adenocarcinoma with pre-operative staging cT3-4N+M0,aged between 18-75 years old, with adequate organ function and having an Eastern Cooperative Oncology Group performance status score ≤2, are randomized in a 1:1:1 ratio to receive neoadjuvant chemoradiotherapy with DT46-50Gy plus concomitant weekly oxaliplatin and 5-Fu, perioperative chemotherapy of FLOT regimen or FOLFOX regimen. The primary end point is disease free survival (DFS), and secondary end point is 5-year overall survival (OS), pathological complete remission (pCR) and treatment safety. The final study analytics are to be conducted at the end of the 5th year after the last patient's enrollment.

Enrollment

900 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • informed consensus of the enrolled patients
  • from 18 to 75 years old
  • proven to be primary adenocarcinoma of EGJ
  • pre-operative staging cT3-4N+M0
  • no prior other chemotherapy and/or radiation against the disease
  • normal function of all other vital organs including heart,liver ,kidney and so on
  • Eastern Cooperative Oncology Group performance status: 0~2

Exclusion criteria

  • history of other malignancy
  • allergic reaction to capecitabine or oxaliplatin
  • enrolled in other clinical trials
  • abnormal GI tract function
  • dysfunction of other organs
  • pregnant or lactating females ,or refuse to receive contraception measures during chemotherapy
  • other situations judged as not adaptive to the study by investigators

Trial design

900 participants in 3 patient groups

Chemoradiation
Active Comparator group
Description:
weekly 5-Fu and oxaliplatin
Treatment:
Radiation: chemoradiation with weekly 5Fu and oxaliplatin
FLOT
Experimental group
Description:
Eight perioperative chemotherapy cycles
Treatment:
Drug: Perioperative mFLOT
FOLFOX
Experimental group
Description:
Twelve perioperative chemotherapy cycles
Treatment:
Drug: Perioperative FOLFOX

Trial contacts and locations

0

Loading...

Central trial contact

Shanshan Li, MD; Xiaohui Zhai, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems